Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA
The crossover dose optimization study aims to refine the dosing profile of the oral therapy and strengthen the design of the planned phase III development program.
The crossover dose optimization study aims to refine the dosing profile of the oral therapy and strengthen the design of the planned phase III development program.
To further assess the safety and efficacy of IHL-42X in patients with OSA, Incannex is conducting a phase 2/3 clinical trial that will be conducted at 55 sites across the United States, Europe, and other countries.